Note: Descriptions are shown in the official language in which they were submitted.
'WO 94/08573
PCT/CA93/00434
- 1 -
USE OF A CELL MEMBRANE PERMEANT CALCIUM BUFFER
FOR REDUCING INJURY OF MAMMALIAN CELLS IN III110
die d of the Invent; ~r
This invention relates to a method of reducing the
damaging effect of an injury to mammalian cells by treatment
with a cell membrane permeant calcium buffer; said calcium
buffers er Vie, pharmaceutical.compositions comprising said
calcium buffers and methods for the preparation of said
l0 pharmaceutical compositions.
Backaround to the rnvent~on
Ischemic or traumatic injuries to the brain or spinal
cord often produce irreversible damage to central nervous
system (CNS) neurons and to their processes. These injuries
15 are major problems to society as they occur frequently, the
damage is often severe, and at present there are still no
effective treatments for acute CNS injuries. Clinically,
ischemic cerebral stroke or spinal cord injuries manifest
themselves as acute deteriorations in neurological capacity
20 ranging from small focal defects-, to catastrophic global
dysfunction-, to death. It is currently felt that the final
magnitude of the deficit is dictated by the nature and extent
of the primary physical insult, and by a time-dependent
sequence of evolving secondary phenomena which cause further
25 neuronal death. Thus, there exists a theoretical time-window,
of uncertain duration, in which a timely intervention might
interrupt the events causing delayed neurotoxicity. However,
little is known about the cellular mechanisms triggering and
maintaining the processes of ischemic or traumatic neuronal
30 death, making it difficult to devise practical preventative
strategies. Consequently, there are currently no clinically
useful treatments for cerebral stroke or spinal cord injury.
vivo, a local reduction in CNS tissue perfusion
WO 94/08573 ~ ; PCT/CA93/0043~
214"~12~
- 2 -
mediates neuronal death in both hypoxic and traumatic CNS
injuries. Local hypoperfusion is usually caused by a
physical disruption of the local vasculature, vessel
thrombosis, vasospasm, or luminal occlusion by an embolic
mass. Regardless of its etiology, the resulting ischemia is
believed to damage susceptible neurons by impacting adversely
on a variety cellular homeostatic mechanisms. Although the
nature of the exact disturbances is poorly understood, a
feature common to many experimental models of neuronal injury
is a rise in free intracellular calcium concentration
([Ca2+];). Neurons possess multiple mechanisms to confine
[Ca2+]; to the low levels (about 100nM) necessary for
physiological function. It is widely believed that a
prolonged, rise in [Ca2+]; deregulates tightly-controlled Ca2+-
dependent processes, causing them to yield excessive reaction
products, to activate normally quiescent enzymatic pathways,
or to inactivate regulatory cytoprotective mechanisms. This,
in-turn, results in the creation of experimentally observable
measures of cell destruction such as lipolysis, proteolysis,
cytoskeletal breakdown, pH alterations, and free radical
formation.
The classical approach to preventing Ca2+ neurotoxicity
has been through pharmacological blockade of Ca2+ entry
through Ca~+ channels and/or of excitatory amino acid (EAA)-
gated channels. Variations on this strategy often lessen EAA-
induced or anoxic cell death in vitro, lending credence to
the Ca2+-neurotoxicity hypothesis. However, a variety of Ca2+
channel- and EAA- antagonists fail to protect against
neuronal injury in vivo, particularly in experimental Spinal
Cord Injury (SCI) , head injury, and global cerebral ischemia.
It is unknown whether this is due to insufficient drug
concentrations, inappropriate Ca2+ influx blockade, or to a
contribution from nor_-Ca2+ dependent neurotoxic processes. It
is likely that Ca2* neurotoxicity is triggered through
different pathways in different CNS neuron types. Hence,
successful Caz+-blockade would require a polypharmaceutical
approach.
~WO 94/08573 ~ ~~ ~ ~ ~ ~ ~ PC'f/CA93/00434
:.
s,
- 3 -
It is well-known that calcium buffer salts and their
acetoxymethyl esters have been used extensively to study
various aspects of cellular neurophysiology. These studies
have focused primarily on experiments involving isolated
tissue preparations in v'tro.
Kudo et ~, Brain Research, 5~8, (I990), pp 48-54,
describe the treatment of an j:,n vitro amphibian neuronal
preparation With Quin-2, membrane permeant calcium buffer,
used to indicate the presence of calcium ions by
fluorescence, for the purposes of determining the effect of
this buffer upon intracellular calcium concentration, and
resistance to excessive electrical stimulation under the
application of the neurotoxin L-glutamate-sodium and the
calcium ionophore A23187, a compound which makes the cell
membrane permeable to the calcium ion.
Scharfman and Schwartzkroin, Science, ,~6, Oct. 13
(1989), pp 257-260, describe experiments 't,~r vitro that
demonstrate. that single neurons that have calcium binding
proteins were more resistant to excessive electrical
stimulation. Neurons with less calcium binding proteins were
less resistant to excessive stimulation. Neurons with no
calcium binding proteins into which a salt of a Ca2+ buffer
was injected by micro-pipette became more resistant to
excessive electrical stimulation than neurons into which the
Ca2+ buffer was not injected. The authors concluded that
effective buffering of intracellular calcium during periods
of excessive excitation is crucial to neuronal survival. A
further conclusion was that supplementing the calcium binding
capacity of vulnerable neurons may prevent cell damage.
Billman GE, McIlroy B, Johnson JD (199 1 , ~~ Elevated
myocardial calcium and its role in sudden cardiac death.~~
FASEB J 5:2586-2592 describes the treatment of cardiac
arrhythmias with membrane permeant calcium chelators by the
administration of a Ca2+ buffer to dogs. The dogs were found
to have a lesser chance of having a fatal electrical
dysfunction of the heart. This article teaches that when
membrane permeant calcium buffers are given to dogs, the
PCT/CA93/0043~
WO 94/08573 '
. ~ 14'~ ~. 2 3 ~ .
- 4 -
electrical activity of their hearts is altered.
Niesen C, Charlton MP, Carlen PL (1991) "Postsynaptic
n
and presynaptic effects of the calcium chelator BAPTA on
synaptic transmission in rat hippocampal dentate granule
neurons.'° Brain Res 555:319-325, shows that the membrane
permeant Ca2* chelator BAPTA-AM can effect electrical
activity of neurons when applied 'fir vitro to an isolated
brain slice preparation. The observed effects are similar
to those seen when BAPTA salt is injected directly into
neurons through a glass microelectrode. However, this
article does not provide data to indicate that BAPTA-AM might
be neuroprotective.
Carpenter-Deyo L, Duimstra JR, Hedstrom O, Reed DJ
(1991), "Toxicity to isolated hepatocytes caused by the
intracellular calcium indicator, Quin 2." J Pharmacol Exp
Therapeut 258:739-746, teaches that membrane-permeant calcium
buffers, (acetoxymethyl esters of Quin 2, Indo 1, Fluo 3,
5,5~-Dimethyl BAPTA) when applied to isolated liver cells,
,j,,D v o, cause toxicity to those cells. This article leads
~ away from a teaching that membrane-permeant CaZ* buffers
prevent toxicity ,~ vivo.
K.G. Baimbridge and K.M. Abdel-Hamid, "Intra-neuronal
Ca2* buffering with BAPTA enhances glutamate excitotoxicity
in vitro and ischemic damage in vivo, "Society for
Neuroscience Abstracts, 1~8, 1992, 571.4, 22nd Annual Meeting,
Anaheim, California, October 25-30, 1992, teaches that when
BAPTA-AM is given to cultured neurons in vitro, the toxicity
of glutamate is greatly enhanced. Further, that when BAPTA-
AM is injected directly into the rat brain in vivo prior to
giving the rat a stroke, the damaging effects of the stroke
are greatly enhanced. This article also leads away from a
teaching that membrane permeant Caa* buffers prevent in vivo
toxicity. '
REFERENCE LIST
The present specification refers to the following
~WO 94/08573 PCT/CA93/00434
- 5 -
publications, each of which is expressly incorporated by
reference herein.
PUBLICAT ONS
1. Armitage P. Berry G (1987), "Statistical Methods in
Medical Research." Oxford: Blackwell ' Scientific
Publications.
2. Billman GE, McIlroy B, Johnson JD (1991), "Elevated
myocardial calcium and its role in sudden cardiac death."
FASEB J. 5:2586-2592.
3. Brint S, Jacewicz M. Kiessling M, Tanabe J, Pulsinelli
W (1988), "Focal brain ischemia in the rat: Methods for
reproducible neocortical infarction using tandem occlusion
of the distal middle cerebral and ipsilateral common parotid
artery." J. Cereb Blood Flow Metab 8:474-485.
4. Buchan AM, Xue D. Slivka A (1992), "A new model of
- temporary focal neocortical ischemia in the rat." Stroke
23:273-279.
5. Carpenter-Deyo L, Duimstra JR, Hedstrom O, Reed JD
(1991), "Toxicity to isolated hepatocytes caused by the
intracellular calcium indicator, Quin 2." J. Pharmacol Exp
Therapeut 258:739-746.
6. Glaum SR, Scholz WK, Miller RJ (1990), °'Acute- and the
long-term glutamate-mediated regulation of [Ca2+]i in rat
hippocampal pyramidal neurons in vitro." Journal of
Pharmacolaav & Experimental hArapeutics, 253:1293-1302.
7. Goldman WF, Bova S, Blaustein MP (1990), "Measurement of
intracellular Ca2+ in cultured arterial smooth muscle cells
using fura-2 and digital imaging microscopy." Cell Calcium
11:221-231.
WO 94/08573 PGT/CA93/0043~
~~,
- 6 -
8. Grynkiewicz G. Poenie M, Tsien RY (1985), "A new
generation of calcium indicators with greatly improved
fluorescence properties." J. Biol. Chem 260:3440-3450.
9. Guthrie PB, Brenneman DE, Neale EA (1987), "Morphological
and biochemical differences expressed in separate dissociated
cell cultures of dorsal and ventral halves of the mouse
spinal cord." Brain Res 420:313-323.
10. Kudo Y, Takeda K, Yamazaki K (1990), "Quin2 protects
neurons against cell death due to Ca2+ overload." Brain Res
528:48-54.
11. Moore EDW, Becker PL, Fogarty KE, Williams DA, Fay FS
(1990) , "Ca2+ imaging in single living cells: Theoretical and
practical issues." Cell Calcium 11:157-179.
12. Niesen C, Charlton MP, Carlen PL (1991), "Postsynaptic
and presynaptic effects of the calcium chelator BAPTA on
synaptic transmission in rat hippocampal dentate granule
neurons." gain Res 555:319-325.
13. Park CK, Mendelow AD, Graham DI, McCullock J, Teasdale
GM (1988), "Correlation of triphenyltetrazolium chloride
perfusion staining with conventional. neurohistology in the
detection of early brain ischaemia." Neuropathol A
Neurobiol 14:289-298.
14 . Randall RD, Thayer SA ( 1992 ) , ''Glutamate-induced calcium
transient triggers delayed calcium overload and neurotoxicity
in rat hippocampal neurons.". J. Neurosci 12:1882-1895.
15. Regan RF, Choi DW (1991), "Glutamate neurotoxicity in
spinal cord cell culture." Neuroscience 43:585-591.
16. Scharfman HE, Schwartzkroin PA (1989), "Protection of
dentate hilar cells from prolonged stimulation by
2 ~. 4 ~ ~. 2 ~ ,
rW0 94/08573 PCT/CA93/00434
- 7 -
intracellular calcium chelation." c'en a 246:257-260.
17. Tymianski M, Charlton MP, Carlen PL, Tator CH (1992),
"Source specificity of early calcium neurotoxicity in
cultured spinal neurons." ,~, Neu osci (Accepted with
revisions Aug 28, 1992).
i8. Williams DA, Fay FS (1990), "Intracellular calibration
of the fluorescent calcium indicator fura-2." Cell Calcium
11:75-83.
19. K.G. Baimbridge and K.M. Abdel-Hamid, "Intra-neuronal
Ca1+ buffering with BAPTA enhances glutamate excitotoxicity
in vitro and ischemic damage in vivo, "Society for
Neuroscience Abstracts, 1~8, 1992, 571.4, 22nd Annual Meeting,
Anaheim, California, October 25-30, 1992.
20. Tymianski, M. and Tator C.H., "A Novel Approach to
Preventing Ca2+ Neurotoxicity with Membrane-Permeant Calcium
Chelators", The Canadian Journal of Neurological Sciences,
#2, 19 May, 1992.
1. U.S. Pat. No. 4806604, issued February 21, 1989, to
Tsien et a for '°Photosensitive Calcium Chelators°' .
2. U.S. Pat. No. 5049673, issued September 17, 1991, to
Tsien et al for "Fluorescent Indicator Dyes for calcium
Working at Long Wavelengths".
3. U.S. Pat. No. 5141627 issued August 25, 1992, to Tsian
et a , for "Chelators whose Affinity for Calcium Ion i_
increased by Illumination."
As .a result of extensive investigations, we have
.. a .
WO 94/08573 ~ PCT/CA93/0043~
_ g _
discovered a method of~reducing the damaging effect of an
injury to mammalian cells in vivo by the treatment of the
cells with a cell membrane permeant calcium buffer.
Summary of the Invention
It is an object of the present invention to provide in
its broadest aspect a method of reducing the damaging effect
of an injury to mammalian cells.
In a further object, the invention provides
pharmaceutical compositions for use in treating mammals to
reduce the damaging effect of an injury to mammalian tissue.
The present invention is based on the discovery oL a
neuroprotective effect against excitotoxic and ischemic
injury by the manipulation of intracellular Caz+ buffering
capacity not requiring Ca2'~ influx blockade. This discovery
is applicable to protection of all neuronal types and further
addresses the possibility that in some cases, Ca2*
neurotoxicity results from internal Caa+ release from
intracellular storage sites.
Surprisingly, we have discovered that a number of
membrane permeant Ca2+ buffers prevent Ca2+ mediated
excitotoxicity in spinal neurons ',fir vitro and significantly
decrease neuronal death and infarction volume following
cerebral ischemia in vivo.
Thus, in its broadest aspect the invention provides a
method of controlling the concentration of Ca2+ ions in the
vicinity of ion channel pores of cells to prevent the
diffusion of toxic amounts of said Ca2* ions to subcellular
sites located near the source of Ca2+ influx to prevent the
triggering of neurotoxic phenomena, said method comprising
administering an effective, non-toxic amount of a membrane
permeant Ca2+ buffer to said cell in vivo.
The invention further provides in one aspect a method
of reducing the damaging effect of an injury to cells in
mammalian tissue and treatment of epilepsy, said method
2~47I23
iW0 94/08573 ~ ~ ' PCT/CA93/00434
- g -
comprising treating said tissue in vivo with a damage
reducing, non-toxic, effective amount of a cell membrane
permeant calcium buffer.
The buffer is, preferably, present in an amount to
reduce or maintain intracellular calcium ion concentration
. to below millimolar levels.
Preferably, the cell membrane permeant buffer is a
calcium ion chelating agent and more preferably a buffer
having a Kp selected from the range 1 x i0~ to 1 x 10~g Molar.
Yet more preferably, the buffer is essentially calcium
selective over other metal ions to provide minimal disruption
to other metal e.g. Fe , Mg , K, Na, ion balances in the
cell.
By the term KD is meant the ratio of the forward and
reverse rate constants of the dissociation of the buffer -
calcium salt (BCa) to buffer (B) and Caz+ ions as represented
by the general equation
Ki
BCa . B + Caz+; Kp ~ y
Kz Kz
To effectively protect mammalian cells against injury,
preferably, the effective amounts of Caz+ buffer inside the
cell should be in the concentration range of 10 ~cM to lomM.
This keeps intracellular calcium concentrations from rising
to millimolar levels during injuries to mammalian cells in
whole animals under conditions which are relevant for
instituting therapy, i.e. clinically-relevant situations,
such as, stroke, as opposed to clinically irrelevant
situations, such as, being torn to bits by an atomic blast.
In a first form, the new compounds of use in the
practice of the invention are comprised of a BAPTA-like
chelator, in which the two halves of the chelator are linked
by a linkage selected from the group comprised of: (a) a
simple 1,2-ethanediyl (-ChzCHz-) moiety having bulky
substituents such as -CH3, -CZHS, or -CHZOH added thereto, (b)
a 2,2-ethanediyl moiety incorporated into a carbocyclic ring
and, (c) a 1,2-ethanedlyl moiety incorporated into a
..
WO 94/08573 PCT/CA93/0043~
- 10 -
heterocyclic ring; wherein the chelator is coupled to a
single 2-nitrobenzyl derivative, which in turn is a
photochemical precursor of a 2-nitrosobenzophenone. In this '
form the new compounds are comprised of a chemical compound
having the generic formula;
N(CH2C02H)2 N(CH2C02H)2
O O
R R9 ~ I . R1
N02 X X rvv2
R3 / \ R3
"I
A A / FI4
R5 RS
and the pharmaceutically acceptable nontoxic salts and esters
thereof wherein:
A is -NOZ or -H;
R1 is selected from the group comprised of -H (unless RZ
is also H), -CH3, -F, -C1, and -Br;
RZ is selected from the group comprised of -H (unless R'
is also H) , -CH3, -F, -C1, -Br, and C~-C4 alkoxy;
R~, R4 and R5 are independently -H, OH, NR~R~, or alkoxy,
or
R3 and R° together are -OCH20- or -OCHZCH20- and R5 is -H,
OH, NR6R~, or alkoxy, or
R4 and R; together are -OCH20- or OCHZCHaO- and R3 is -H,
OH, NR6R~, or alkoxy;
X is selected from the group comprised of -OH, alkoxy,
-C1, Br, -NRbR~, -OCOCH3, -OCOCF3, - OCOCHZNHZ, -OPO~H,
and -OSOZCH~;
R6 and R' are independently -H, methyl or ethyl;
RR and R9 are independently -H, -CHI, -C2H5, or -CH~OH
except that both may not be -H simultaneously; or Rg and
R9 together are - (CHZ) ",-Y- (CHZ) "- where m and n are
su~s-~rrur~ s~EE~'
-WO 94/08573 PCT/CA93/00434
- 11 -
independently 1 or 2 and Y is selected from the group
comprised of -CHZ-, -O-, -NR~- -S- and -S-S-
and
W is -H, -OH, or -NHR6.
In a second form, the compounds are comprised of a
BAPTA-like chelator, in which the two halves of the chelator
are linked by a linkage selected from the group comprised of:
(a) a simple 1,2-ethanediyl (-CHZCHZ-) moiety having bulky
substituents such as -CHa-, -CZHS, or -CHZOH added thereto, (b)
a 1,2-ethanediyl moiety incorporated into a carbocyclic ring
and, (c) a 1,2-ethanediyl moiety incorporated into a
heterocyclic ring; wherein the chelator is coupled to two 2
nitrobenzyl derivatives, themselves photochemical precursors
of the related 2-nitrosobenzophenones. In this form, the
compounds are comprised of a chemical compound having the
generic formula:
N(CH2C02H)2 N(CH2C02H)2
O 4
R8 R9 ~ I Ri
R2
R
IH
~ A
R 5
R
and the pharmaceutically acceptable non-toxic salts and
esters thereof wherein:
A is -NOZ or -H;
R;, R4 and RS are independently -H, OH, NRbR~, or alkoxy,
or
R; and R4 together are -OCH20- or -OCHZCH20- and R5 is -H,
OH, NR6R~, or alkoxy, or
R4 and R5 together are -OCH20- or -OCHZCHzO- and R3 is -H,
OH, NR6R~, or alkoxy;
X is selected from the group comprised of OH, alkoxy, -
SUB: T~TUTE SHEET
WO 94/08573 ~ ~ ~ PCT/CA93/0043
12
Cl, -Br, -NRbR~, - OCOCH3, -OCOCF3, °OCOCHZNH2, -OPO~H, and
-OSOZCH3;
R6 and R' are independently -H, methyl or ethyl;
R& and R'' are independently -H or -CH3, or -C2H5 or -CHzOH
except that both may not be -H simultaneously; or Rg and
R9 together are - (CHZ~",-Y- (CHZ) "-where m and n are
independently 1 or 2 and Y is selected from the group
comprised of -CHZ-, -O-, -NRb-, -S-, and -S-S-;
and
W is -H, -OH, or -NHR'~.
In a third form, the compounds of use in the practise
of the invention fall within the general formula:
N(CH 2COOH) 2 N(CH 2COOH) 2
O O
/ E'~E21 /
W
Z1 ~ ~ n
Q1 / Y WQ2
Z3 Z4
and the pharmaceutically acceptable non-toxic salts and
esters thereof wherein:
E~ and EZ are independently H, CH3 CZHS, CHZOH,
COOH, or CHzCOOH, or EI and E2 together are
-(CHZ)m-V-CHZ)"- where m and n are independently 1 or 2
and V is selected from the group consisting of -CHZ-, -
O-, NH-, -NMc-, -S-, and -S--S-;
W is H, OH, or COOH;
X is H, Me, COOH, F, Cl, Br, I or NOz
Y is -O-, -NMe-, -S-, -CHZ-, -CMe2-, -CFZ-,
or a direct sigma bond making a five-membered central
ring;
Z', Z~, Z3, and Z4 are independently H, F, C1, Br, I, or
Me, and Q1, Q2 equal R,RZN-,
SU~.~sTtTU'~E SHEEP
~14"~~.~3
WO 94/08573 . PCT/CA93/00434
- 13 -
or HO-, O=, where R' and RZ are independently selected
from the group consisting of H, Me, and Et; or Z' , Q' ,
or Z~ together are
- ( CHZ ) ~-N- ( CHZ ) s
and ZZ, Q2, Z4 together are
- ( CHZ ) 3-N- ( CH2 ) s
Preferably, the tetraacetic acid esters are alpha-
acyloxyalkyl esters, and more preferably, the alpha-
acyloxyalky esters are acetoxymethyl esters.
In a fourth form, the chemical compound has the general
f ormu 1 a
N(CH 2COOH) 2 N(CH ~COOH) 2
E1
W
Z~ /~,Z2 Z Z2
Q1 ~ Y ~ Q2 Q1 Q2
Z3 Z4 Z;~ Z4
and the pharmaceutically acceptable non-toxic salts and
esters thereof wherein:
EI and EZ are independently H, CH3, CZHS, CHZOH, COOH, or
CHZCOOH, or E1 and EZ together are -(CHZ),~1-V-CHZ)~- where
m and n are independently 1 or 2 and V is selected from
the group consisting of CHZ-, -O-, -NH-, -NMe-, -S-, and
-S-S-;
W is H, OH, cr COOH;
X is H, Me, COOH, F, C1, Br, I, or NOZ;
Y is -O-, -NMe-, -S-, -CHZ-, -CMez-, -CF2-, - CO. -
or a direct sigma bond making five-memhered central
ring;
Sl~~: fii~'tJ°~E S~-~iEET
WO 94/08573 ~ ~ ~ ~ ~ ~ ~ s' ' ' ' y' '- PCT/CA93/0043~
--< 14. -
Z', Zz, Z3, and Z4~'lare independently H, F, C1, Br, I, or
Me, and Q', Qz equal R,R2N-,
RIRzN-
or HO-, O= or R,RZN-, O-, where R' and Rz are
independently selected from the group consisting of H,
Me, and Et; or Z', Q', Z3 together are
- ( CHz) s-N- ( CHz) S-
and Zz, Qz, Z4 together are
- ( CHz) ~-N- ( CHz) s-
In a fifth form, the chemical of use in the practise of the
invention is a compound of the formula:
N-(CH 2COOH) g N(CH pCOOH) 2
CH-CH
R1 / ~ 6 O R3
R2 R5 R R4
and the salts or the non-polymeric esters thereof wherein
R' and R; are each independently selected from -H,
OH, -CH3, -F, C1, -Br, -I, -COOH.
-CN, -NOz or -NHR~ wherein R', is independently selected
from -H, methyl or ethyl;
Rz is -(C=O) CR8-N-N, wherein Rg is independently selected
from -H, C1-C4 alkyl, phenyl, -COOH, -COORS -(C-O) CH3,
or -CF3 wherein R~ is defined hereinabove;
R4 is independently selected from Rz, -H, -CH3,
-CHZCH~, -F, -C1-, -Br, -I, -COON,
-CN or -NOz;
R5 and R6 are each independently selected from -H,
2 5 -CHI , -C2H5, phenyl , or -CH20H , or R5 and Rb together form
- (CHz) ",-Y- (CHz) "- where m and n are each independently 1
or 2, and Y is selected from -CHz-, -O-, -NHR~, -S- or -
S-S-, wherein R' is defined hereinabove.
SUSSTtTUTE SHEET
WO 94/08573 P PCT/CA93/00434
- 15 -
DEFINITIONS
In the present specification and claims, reference will
be made to phrases and terms of art which are expressly
defined for use herein as follows:
As used herein, "[Ca2+]i" means intracellular free
calcium.
As used herein, "EGTA" means ethylene glycol bis(-beta-
aminoethyl ether-)-N,N,N',N'-tetraacetic acid.
As used herein, "BAPTA" means 1,2-bis(2-
aminophenoxy)ethane N,N,N',N'-tetraacetic acid.
As used herein, "quip-2'~ means 2-[[2-
bis(carboxymethyl)amino]-5-methylphenoxy]-6-methoxy-8-
bis(carobxymethyl)amino]quinolline.
As used herein, "BAPTA-like" means substituted
derivaties of BAPTA which retain the essential characteristic
of two bis(carboxymethyl)amino-substituted phenyl rings, said
rings being linked at the positions ortho to the amines
through a four atom bridge wherein the atom adjacent to each
phenyl ring is N or O and the two center atoms are each C.
By this definition, it is means that "BAPTA-like" includes
compounds like gain-1 and gain-2.
As used herein,.pharmaceutically acceptable esters mean
those readily hydrolyzable esters which are known and used
in the pharmaceutical industry, especially alpha-acyloxyalkyl
esters.
As used herein pharmaceutically acceptable non-toxic
salts mean carboxylic acid salts wherein the counterion or
ions are all Na, K, NR4=+ (where R=H, C,-C4 alkyl or a mixture
thereof), choline, N-methyl-glucamine, Ca, or Mg, or some
combination of these counterions, or some combination of acid
salts or these counterions plus free acid groups.
By the term °'cell membrane permeant calcium buffer" is
meant a calcium ion chelating agent which per se is membrane
permeant or a membrane permeant derivative thereof which
releases said calcium ion chelating agent within the cell,
for example ester, amide and other suitable derivatives which
WO 94/08573 ~ ~ ~ ~ PCT/CA93/004
16
i
release the chelating, agent per se, and pharmaceutically
acceptable non-toxic's~ailts thereof.
Examples of most preferred calcium buffers of use in the
practise of the invention are those known in the art as
follows:
BAPTA - AM (1,2 - bis (2-aminophenoxy) ethan - N,N,N',N'-
tetraacetic acid - acetoxymethyl ester;
EGTA-AM (ethyleneglycol bis 2-aminoethyl ether) N,N,N',N'-
tetraacetic acid acetoxymethyl ester;
5,5~ dibromo BAPTA-AM
5, 5~ - difluoro BAPTA-AM
4 , 4~ - dif luoro BAPTA-AM
The approximate dissociation constants for Ca2+ of the
above buffers are set out in following Table 1.
TABLE 1
Chelator Approximate Rd **
EGTA-AM 100 wM
BAPTA-AM 160 nM in 0 mM Mg
440 nM in 1 mM Mg
5,5'-BrZBAPTA-AM 3600 nM
5,5'-FZBAPTA-AM 660 nM in 0 mM Mg
706 nM in 1 mM Mg
4,4'-F~BAPTA-AM 4600 nM in 0 mM Mg
** Molecular Probes Inc. Eugene, Oregon.
The method of reducing the damaging~effect of an injury
to mammalian cells applies to the application of the cell
membrane permeant calcium buffer by way of treatment after
the injury has been sustained.
The structure of BAPTA-AM arid its derivatives is shown
hereinbelow:
~WO 94/08573 ~ ~ ~ ~ ~ ~ . . PGT/CA93/00434
- 17 -
C00 A~1 A~.OOC
N ~cxo.-w N
0~0
R,
Rs
C0o' ' OOC
-pp~-~
N ~0 N
0~0
R,
R,
wherein BAPTA: Rl=R2=H
4 , 4' -FZ BAPTA: Rl=Fl RZ=H
, 5 ~ -FZ BAPTA : R~=H, R2=F
5 , 5 ~ -Br2 BAPTA : R~=H , RZsBr
The BAPTA-AM is de-esterified intracellulary to form the
active chelating compound, by the process:
0 0
R-~~ ~ R-~H=OH -~ R-COH
0 0
CH~~OH H~H
WO 94/08573 ~ ~ ~ ~ ~ ~ ~ . . . PCT/CA93/0043~
- 18 -
In an alternative method according to the invention the
cell membrane permeant calcium buffer can be used as a
prophylactic to reduce the~extent of the injury to the cell
by the application of the buffer prior to the injury being
sustained.
The method of the present invention is applicable to
injuries caused by a reduction in blood flow, oxygen flow
nutrient flow, trauma, radiation, toxin exposure, infection,
neoplasia or inflammation, to said tissue; and for the
treatment of epilepsy.
Thus, treatment of a patient with a membrane permeant
calcium buffer is performed under two major situations: 1)
pre-treatment, when injury to the nervous system is
anticipated, for example, as in upcoming surgery, and 2)
post-treatment. The membrane permeant calcium buffer may be
administered, for example, by one of the following four
routes, namely, intravenously, intra-arterially,
intrathecally, i.e. within the membranes surrounding the
nervous tissue, or intraventricularly, i.e. directly into the
chambers inside the brain. The buffer is, typically,
administered in a suitable vehicle, in which the active
ingredient buffer is either dissolved or suspended in a
liquid and which permits the buffer to be delivered from the
bloodstream into the nerve cells, thereby crossing the
bloodbrain barrier without undue toxicity or from the
cerebrospinal fluid into nerve cells without undue toxicity.
Solutions would be, typically, alcohol solutions, dimethyl
sulfoxide solutions, or aqueous solutions containing, for
example, polyethylene glycol containing, for example,
polyethylene glycol 400, Cremophor-EL or Cyclodextrin. Such
vehicles are well-known in the art, and useful for the
purpose of delivering a membrane permeant calcium chelator.
Generally, in order for membrane permeant calcium buffers to
work, they must be administered in a solvent that would
prevent them from precipitating in the otherwise aqueous
environment of the bloodstream. The solvent
dimethylsulfoxide, DMSO, is one such useful solvent. Thus,
r
~WO 94/08573 . PCT/CA93/00434
- 19 -
treatment of a patient with a membrane permeant calcium
buffer is performed.
Particular mammalian cells subjected to treatment
according to the present invention are those of the nervous
system, heart, liver, spleen, kidney, adrenal glands,
gastrointestinal tract, vascular smooth muscle and the skin.
The cell membrane permeant calcium buffer may be
administered to the mammal by methods well-known in the art,
namely, intravenously, intra-arterially, topically, sub
l0 cutaneously, by ingestion, intra-muscular injection,
inhalation, and the like. Preferably, for treatment of nerve
cells, the most effective methods of administration are 1)
intravenously; 2) intra-arterially, 3) intra-thecally and/or
intra-cisternally; and 4) intra-ventricularly.
We have found that in the method according to the
invention a sufficient period of time must be allowed for the
cell membrane permeant calcium buffer to reach the damaged
tissue and to enter the cells, and, if a derivative thereof,
generate the buffer per se in vivo.
In a further aspect, the invention provides a cell
membrane permeant calcium buffer for reducing the damaging
effect of an injury to cells in mammalian tissue.
Preferably, the buffer is a chelating agent for the
calcium ion, and more preferably, a buffer that is
essentially calcium ion selective over other metal ions, such
as for example, Fez+, Mgz+~ k+ and Na+. Calcium buffers
having a KD selected from the range 1 x 10'~ to 1 x 10'8 Molar
are most preferred.
Specific cell membrane permeant calcium buffers of value
in the present invention are BAPTA-AM; EGTA-AM; 5,5'
difluoro BAPTA-AM and 4,4~ - difluoro BAPTA-AM, and 5,5'
dibromo BAPTA-AM, as hereinbefore defined.
In yet a further aspect, the invention provides
pharmaceutic compositions for reducing the damaging effect
of an injury to cells in mammalian tissue comprising a cell
membrane permeant calcium buffer as hereinbefore defined in
admixture with a suitable pharmaceutically acceptable
. .
WO 94/08573 PC1'/CA93/004~
- 20 -
diluent, carrier or adjuvant. It will be understood by the
man skilled in the art that the pharmaceutically active cell
membrane permeant calcium buffer should be present in
pharmaceutically effective amounts.
In a still yet further aspect, the invention provides
a process for the .manufacture of a pharmaceutical composition
for reducing the damaging effect of an injury to cells in
mammalian tissue or the treatment of epilepsy, said process
comprising admixing a cell membrane permeant calcium buffer
with a pharmaceutically acceptable carrier therefor.
~t~~led Description of the Invention
METHODS FOR EXPERIMENTS IN PRIMARY NEURONAL CULTURES.
Tissue culture technique. Spinal neurons from E13 fetal
Swiss mice were cultured for two weeks on glass coverslips
coated with poly-D-lysine hydrobromide (M. W. 30,000-70,000,
Sigma, P-7280). Dorsal root ganglia were excluded during the
dissection. The neurons were as conventional dissociated
primary neuronal cultures (Guthrie et al. 19872. A11 cultures
were maintained in a humidified 5%-C02/95%-air atmosphere at
36.5°C, and were fed biweekly with a medium containing 58%
minimal essential medium (MEM), 20% fetal bovine serum, and
20% distilled water, supplemented with (in mM) 40 glucose,
11.6 NaHC03, 0.4 L-glutamine and Insulin-Toronto, 80
biological units/100 ml of medium, balanced to 300 mOsm and
25_ pH 7.4 in 5% C02. At four days in vitro, the cultures were
treated with 20~g/ml 5'-fluoro-deoxyuridine and 50~g/ml
uridine for 24 hours to inhibit proliferation of non-neuronal
cells. No antibiotics were employed. The presence of neurons
and astrocytes in the cultures was confirmed by
immunocytochemical staining for neurofilament, ~neuron-
specific enolase, and glial fibrillary associated protein.
L_o_adina of neurons with calcium indicator and Ca2+ buffers.
The cultures were incubated for 70 minutes in loading medium
214'~~.2~
~WO 94/08573 PCT/CA93/00434
- 21 -
(78% MEM and 20% distilled water, supplemented to 40 mM D-
Glucose, 1.0 mM Mg2*, 20 mM HEPES, pH of 7.4 in 5% Co2.)
containing l~cM furs-2-acetoxy-methyl ester (fura-2/AM;
Molecular Probes Inc.) in a final concentration of 0.2%
dimethyl sulfoxide (DMSO). After 10 min of loading with
fura-2, the loading medium was supplemented with a membrane-
permeant Ca2* buffer (Table 1) dissolved in the medium to its-
desired final concentration. The lipophilic membrane-permeant
fura-2/AM penetrates into neurons and is converted by the
action of intracellular esterases into a membrane-impermeant
fura-2 salt, which is trapped intracellularly as a specific
calcium indicator (Grynkiewicz et al. 1985). Non-fluorescent
BAPTA and its derivatives permeate into neurons in the same
manner. After loading, the cultures were washed for 30
minutes in plain loading medium to attenuate any background
fluorescence from residual extracellular calcium indicator.
Instrumentation. Cultures loaded with indicator were mounted
in a microscope-stage incubator (Medical Systems Corp. model
TC-202), and viewed with an inverted microscope (Nikon
Diaphot-TMD equipped with Xenon epifluorescence optics)
through a fluorite oil-immersion lens (Nikon CF W-F x40, NA
= 1.3) in contact with the coverslip bottom. A second-
generation microchannel-plate intensified CCD-array camera
(Quantex Corp. Model QX-100) recorded the 510nm fluorescence
emissions from fura-2 in neurons excited through narrow band-
pass filters (340~5nm; 380~6.5nm; Omega Optical) housed in
a computer-controlled filter wheel. All data were gathered
on a~80386-based personal computer, and were archived on an
.optical disk drive (Panasonic, LF-5010). The system allowed
for a time-resolution of 2 seconds between successive [Ca2*];
measurements.
Calibrat?on. [Ca2*]; was determined using ,~ vitro-derived
conversion factors used to generates a calibration curve
described by the equation [Caz+]; = Kd(F~/F~"~) [ (R-~) / (~-R) ]
in which Kd = 224 nM, the dissociation constant for fura-2
PCT/CA93/0043~
WO 94/08573
- Z2 -
(Grynkiewicz et al. 1985; for reviews see Moore et al. 1990;
Goldman et al. 1990) . To determine (F,~/Fm"~) , R~ and Rte, a
glass-bottom slide with 100~cL~chambers containing control
solution (see below), l~cM furs-2 pentapotassium salt, and
either a saturating calcium load ( 1 mM) , or zero calcium with
mM EGTA was imaged. A third chamber containing control
solution without furs-2 was used to generate background
images. Typical values for conversion factors were: F~/F
10.31, Rte, = 0.54, F~= ~ 10.48. To generate ratio images,
10 eight raw fluorescence images gathered at each wavelength
(34onm and 380nm) were averaged, background subtracted, and
converted on-line to calibrated furs-2 ratio images
(340nm/38onm) using a pseudocolor display of [Ca2+];. New
background images were obtained for each experiment. The
system was recalibrated following any adjustments to the
apparatus. When plotting the time course of neuronal [Caz+];
(e.g. , Fig. 1A) , if the measured [Ca2+]; eventually rose to
values exceeding those of the meaningful range of the
calibration curve, the tracings were truncated for the
purpose of clarity at values around 15o0nM [Ca2+];
(asterisks) . It was not possible to reproduce in the present
neuronal preparation the i~ vivo calibrations described by
others for non-neuronal cells (e.g. , Williams and Fay, 1990) ,
as spinal neurons exposed to varying concentrations of
calcium ionophore (4-Bromo-A23187 at 0.5-10~,M) always
underwent lysis prior to achieving [Ca2+]; approaching those
in the extracellular medium.
Drugs and solutions. The control solution contained in mM:
130 NaCl, 1.3 CaCl2, 4.5 KC1, 22 D-glucose, 20 HEPES, 1.0
sodium pyruvate, and 0.001 glycine. All solutions were
adjusted to 300 mOsm, pH of 7:4, and 36.5°C prior to
administration. EGTA/AM (Calbiochem) and all BAPTA-AM
derivatives (Molecular probes inc. ; see Table 1 were prepared
as 30MM stocks in dry DMSO and dissolved to their final
concentrations in the loading medium. During experiments, the
final DMSO concentrations never exceeded 1.0%, a level which
~VVO 94/08573 ~ ~ ~ ~ . PCT/CA93/00434
- 23 -
had no effect on [Ca2*]; or on neuronal survival in pilot
studies.
~teuronal viabilitv assays. Following each experiment, the
cultures were incubated for 10 min at 36.5°C with 2~M
ethidium homodimer and 1~CM calcein-AM. Ethidium homodimer
binds to nuclear material in dead cells, whereas calcein-AM,
by virtue of the enzymatic hydrolysis of the
ester, is retained in living cells (Moore et a1.1990). Thus,
when excited in the fluorescein range (485-500nm) , dead cells
appear red-orange, whereas living cells appear green. As a
further measure of cell viability, the cultures were also
superfused for 2 minutes with 0.4~ trypan blue stain, and
neuronal viability was confirmed with brightfield microscopy.
Experimental -procedure. All experiments were performed at
36.5~5°C. Neurons loaded with furs-2 were superfused with
control solution at 1-2m1/min. [Ca2*]; was measured
simultaneously in several neurons in the field throughout the
experiments . Baseline [ Ca2* ]; was registered for 5-15 minutes ,
following which the neurons were exposed to a 5o min
challenge with 250~M glutamate (GLU). The rise in neuronal
[Ca2*]; was measured every 2 sec from the onset of the
challenge until peak [Ca2*]; was registered. Then, the
frequency of [Ca2*]; measurements was gradually reduced as
[Ca2*]; declined, reaching a measurement every 3 min when the
decline in [Ca2*]; ended. Following the 50 min challenge,
neurons in some experiments were again superfused with
control solution for a further 30 min.
Data Analysis. Statistical analyses were performed using
ANOVA with post-hoc multiple comparisons using the Newman-
Keuls procedure to determine significant differences between
individual group means (see section 7.4 in Armitage and
Berry, 1987). Linear and logistic regression analyses were
employed to model and test probabilities of cell death. Where
appropriate, survival analysis methods using the Kaplan-Meier
~ ~. ~'~ ~. 2 ~ .
WO 94/08573 . . ~ PCT/CA93/0043~
- 24 -
survival model (see section 14.5 in Armitage and Berry, 1987)
were employed to test time-dependent effects. Unless
otherwise stated, mean values are provided with their
standard errors (mean ~ s.e.):.
METHODS FOR EXPERIMENTS IN ISOLATED RAT BRAIN SLICES.
Drucxs and solut'ons: Calcium Crimson-AM, a fluorescent,
membrane-permeant BAPTA-based Ca2+ indicator (Molecular
Probes Inc, C-3018), was dissolved in dry DMSO (400mg in
0.5m1 DMSO) immediately prior to each experiment. Artificial
cerebrospinal fluid (ACSF) contained in mM: NaCl 125, KCl
2.5, NaH2P04 1.25, MgClz 2, CaCl2 2, NaHC03 25 and glucose 10,
with pH 7.4 aerated with 5% COZ - 95% 02. The osmolarity of
the ACSF was 300 ~ 5 m.osmol.
Exuerimental procedure: Fischer 344 rats weighing 240-300
grams were anaesthetized with 1.5% halothane (Fluothane,
Ayerst Laboratories, Montreal) and nitrous oxide/oxygen
70%/30%, and maintained with positive pressure ventilation
via a tracheostomy. Mean arterial pressure (MAP) measurements
and venous access were obtained through polyethylene
catheters inserted into the femoral artery and vein
respectively. MAP was maintained at 80mm Hg throughout the
experiments. Core body temperature (measured with a rectal
probe) and temporalis muscle temperature were monitored in
each animal and maintained at 37~0.5°C. The protocol for
loading rats with Calcium Crimson is shown in the inset of
Fig. 5. Briefly, 400mg of Calcium crimson-AM in 0.5 ml DMSO
were then injected into the rat femoral vein over 60 min
using an infusion pump. Control animals received 0.5 ml DMSO
alone. Rats were always infused in pairs, with one animal
serving as control. After a further 3 hours, the rats were
decapitated, and transverse brain slices (400 Vim) were
obtained and maintained in ACSF at room temperature until
used.
A rat brain slice loaded with Calcium Crimson was placed
WO 94/08573 ' ' PCT/CA93/00434
- 25 -
alongside a control slice in a glass-bottomed chamber. They
were viewed at room temperature with a laser-scanning
confocal microscope (Bio-Rad MRC 600) through a fluorite lens
(Nikon CF W-F x 10). In each experiment, both slices
(control and loaded) were viewed with the same confocal
settings, using a Rhodamine filter cube.
METHODS FOR EXPERIMENTS ~T VIVO.
a) Surgical Preparation:
Forty-one male Fischer 344 rats (weight 275-340 grams)
were anaesthetized with 2% Halothane and a mixture of nitrous
oxide/oxygen (1:1) in a bell chamber. A tracheostomy was
performed and mechanical ventilation initiated (Harvard
rodent ventilator, Model 683). Maintenance anaesthesia was
1% Halothane titrated to blood pressure. Polyethylene tubing
was inserted into the femoral artery and vein for continuous
blood pressure monitoring and for drug and fluid
administration. The ventilation was altered according to the
arterial~blood gases taken at regular intervals. Temperature
was monitored with a rectal probe as well as a micro-probe
placed in the temporalis muscle, and an overhead lamp was
used to maintain the recorded rectal temperature at 37
degrees Celsius. Vascular catheters were filled with
heparinized saline (100 IU/ml).
b) Experimental Design:
Two independent, blinded experiments were carried out.
After the surgical preparation was complete and the blood
gases had stabilized, the animal would be randomly allocated
to an experimental group and begin an infusion (Harvard
Infusion pump, Models 901,903) with a volume of o.5cc over
a time period of 60 minutes. The cerebral ischemia was
started 4 hours,after the beginning of the infusion.
i) Study I:
Animals were randomized into two groups, one
WO 94/08573 _ ~ ~ ~ ~ ~ PCT/CA93/0043
,~ ..
- 26
receiving an infusion of DMSO and the second receiving
BAPTA/AM (18 mg/kg) in an identical solution of DMSO.
ii) Study II
There were five experimental groups in the second
study, carried out by a different surgeon than the first
study. Random allocation of animals was performed into the
following infusion regimes:
1. saline
2. DMSO
3. BAPTA/AM in DMSO
4. 4,4' diflouro BAPTA in DMSO
5. 5,5' diflouro BAPTA in DMSO
c) Cerebral Ischemia:
Thirty minutes prior to the completion of the 4 hour
pre-treatment period, the surgical preparation for middle
cerebral occlusion was started. The procedure used in both
studies has been previously described (Brint et al 1988,
Buchan et al 1992 ) . Brief 1y, the left common carotid was
exposed through the tracheostomy incision and the distal left
middle cerebral artery was exposed via a small temporal
craniectomy. As the gre-treatment period concluded, the
common carotid was occluded with an aneurysm clip and the
middle cerebral artery was cauterized .and cut with the
assistance of the operating microscope. The incisions were
closed with sutures. '
The post-ischemic period lasted 4 hours during which
mean arterial blood pressure and arterial blood gases were
monitored continuously. Core (rectal) and temporalis muscle
temperature was maintained at 37~0.5 degrees Celsius.
d) Outcome Methods:
After completion of the 4 hour post-ischemic time
period, an infusion with Triphenyltetrazolium chloride (TTC)
and formaldehyde was performed as previously described (Park
WO 94/08573 ~ ~ ~ ~ ~ ~ t ' ~ PGT/CA93/00434
- 27 -
et al 1988). briefly, the ascending aorta was cannulated
through an abdominal incision and heparinized saline was
infused until the effluent via a hole in the inferior vena
cava was clear. Infusions of TTC followed by formaldehyde
at a perfusion pressure of 80 mmFig concluded the perfusion
fixation. The heads were removed and placed in formaldehyde
for 24 hours before the brains were removed.
The brains were sectioned in eight coronal planes and
evaluated for TTC staining. Two individuals, blinded to the
experimental groups, recorded the TTC defect. The infarction
volume was calculated on an image analysis system ( MCID,
Imaging Research Inc.) from the cross-sectional area of TTC
defect in the eight coronal planes. The coronal brain slices
were embedded in paraffin, cut by microtome into 7 micron
sections and stained with hematoxylin and eosin. The
histology was reviewed by two individuals, again blinded to
the experimental group, and the infarction area demarcated
on each of the eight coronal sections. The volume of
infarction and the percent of cortex infarcted were
calculated using the image analysis system.
Statistical analysis involved a comparison of the
infarction volume or percent cortical infarction between
treatment groups by Student T-Test for Study I and an
analysis of variance with post hoc T-Tests for Study II.
Correlation coefficients were calculated for TTC versus
histological evaluation of infarction volume and the
variability between individuals assessing the infarction.
DETAILED DESCRIPTION OF THE DRAWINGS
Figure 1 represents a graph of time course of changes
in intracellular calcium during neurotoxin L-glutamate-sodium
application.
Figure 2 represents graphs giving the effects of
membrane-permeant Ca2+ buffers on [Ca2+]; and secondary Caz'
overload. Individual tracings show the time-course of [Ca2+],
in single neurons challenged with 250uM glutamate (GLU; black
WO 94/08573 ' ' PCT/CA93/0043
- 28 -
bar) . A. Stability of baseline [Caz*]; in the absence of GLU.
B. In the absence of exogenous [Caz*] buffers, GLU evokes a
large primary [Ca2*]; transients (arrow) which recovers to a
lower ~~plateau~~, followed , by secondary [Ca2*] overload
(asterisks) in 12/15 neurons. C-F. Time course of [Ca2*]; in
neurons pre-treated with BAPTA-AM (D,D), EGTA-AM (E), and
4,4~F2-BAPTA-AM(F). At sufficient concentrations, BAPTA and
EGTA (Kd - 100nM) attenuated the peak [Ca2*]; rise, and
protected neurons against secondary Ca2* overload (D, E).
4, 4 ~FZ-BAPTA, a low affinity Ca2* buffer (Ks ~ 2600nM) was
toxic to spinal neurons (F).
Figure 3 represents graphs showing the relationships
between Ca2* buffers, [Ca2*];, Caz*]; -affinity (Kd) , and
neuronal survival following glutamate challenge. Neurons
were superfused with 250uM glutamate as in Fig. 2. Symbols
in A-C show mean values for all neurons treated with a given
Ca2* buffer (total 450 neurons.) Standard errors are shown
where they exceed the symbol size. A. Relationship between
Kd and the fraction of dead neurons following recovery from
the initial [Ca2*]; transient (Plateau [Ca2*];) . B.
Relationship between Kd and the fraction of dead neurons in
each Ca2* buffer group. C. Dominance of intracellular Ca2*
buffering by exogenous buffers, illustrated by the linear
relationship between the fraction of dead neurons and plateau
[Ca2*]; in neurons loaded with Ca2* buffers (Correlation
Coefficient = 0.986, p 0.0003). Note that control neurons
(square) do not fall on this line. D. Effects of various
Caa* buffers on neuronal survival as gauged by trypan blue
and by secondary Ca2* overload. Bars with different symbols
are statistically different at p 0.001.
Figure 4 shows the representative effects of BAPTA-AM
on cortical infarction volume as determined by TTC method
(MCA & CCA occlusion). Rats treated with BAPTA-AM or its
derivatives (Rat no. 4) sustained significantly smaller
cortical infarctions than controls (Rat no. 6) after distal
middle cerebral and ipsilateral common carotid occlusion.
Infarction volumes in every case were computed from
~1~4'~i23
'WO 94/08573 PCT/CA93/00434
- 29 -
infarction area measurements performed on eight standardized
coronal brain slices as, shown here. The same templates were
utilized for infarction volume assessment by
triphenyltetrazolium chloride perfusion (TTC), and by
standard histological means.
Left hand diagram represents BAPTA-AM, 18 mg/Kg, delivered
in 0.5 ml DMSO to rat no. 4; and right hand diagram
represents control, 0.5 ml DMSO, with rat no. 6.
Figure 5 represents graphs showing that BAPTA-AM reduces
the volume of infarction following focal cerebral ischemia.
A. in a randomized, double blinded, placebo controlled trial,
pretreatment with BAPTA-AM or its derivatives reduced focal
infarction volume by 50% as compared with controls. Infarct
volumes were assessed by two methods. First, by
triphenyltetrazolium chloride (TTC) perfusion, a technique
which delineates the infarction area by vitally staining non-
infarcted tissues red, and second, by histological assessment
of the infarction area. Infarction volumes were calculated
as shown in Figure 4. Results are shown as means ~ standard
deviations. 8. Relationship between infarct volume
assessment with TTC and histology. Inset (top): The surgical
protocol for both double-blinded randomized trials.
Figure 6 represents a graph showing that in a second
double-blinded randomized trial BAPTA-AM and its high Kd (low
Ca2+ -affinity) derivatives reduce the volume of infarction
following focal cerebral ischemia. In a second randomized,
double blinded, placebo controlled trial, pretreatment with
BAPTA-AM (Kd ca. 160 nM) reduced focal infarction volume by
up to 66% as compared with controls. Results are shown as
means ~ standard deviations.
PART 1' Cell Culture Experiments
The application of exogenous glutamate to cultured CNS
neurons is a commonly employed, and accepted model of
neurotoxicity ~ vitro, and approximates the excitotoxic
phenomena occurring in the CNS ~n_ v'vo. Accordingly, a
WO 94/08573 PCT/CA93/0043~
- 30 -
glutamate challenge was used as ,the cytotoxic stimulus in the
present experiments. Using,~~e digital imaging approach,
[caz+]; was measured simultaneously in several neurons (mean:
neurons per experiment, range 4-2?). A total of 667
5 spinal neurons in 68 experiments were studied. Twenty three
neurons (3.44%) were excluded from study because of
consistently elevated [Caz+]; (>250nM) during baseline
measurements, leaving 644 neurons for statistical analyses
of physiological parameters. All neurons were cultured for
10 14-17 days to ensure a uniform, high susceptibility to
glutamate neurotoxicity between cultures (Began and Choi,
2991). At this stage in vitro, the neurons exhibited
extensive neurite formation, and were easily distinguished
from surrounding cells by the presence of oval, phase-bright
somata and by the morphology of their processes. The somal
diameters of neurons used in these studies averaged 17~5.7~m
(mean ~ std. dev.). All related experiments were routinely
performed in sister cultures, and the results were replicated
in cultures from later dissections.
"Caz+ derecrulation" is an early 'ndicator of neuronal death.
Figure 1 shows that when spinal neurons were exposed to
a 50 min challenge with 250~CM glutamate (GLU) , [Caz+]; rose
rapidly, and then decayed to a lower "plateau°'. Following
termination of the challenge, [Caz+]; in surviving neurons
remained at the new plateau, or returned toward basal levels.
However, many neurons underwent a delayed, sustained, and
generally irreversible rise in [Caz+]; which often exceeded
tha dynamic range of the Caz+ indicator. This phenomenon
closely paralleled neuronal staining with the vital dye
trypan blue, indicating that it must have preceded- or
coincided with- neuronal death. Observations in spinal
neurons are in agreement with the recently reported
observation that glutamate-induced [Caz+]; transients can
trigger delayed Caz+ overload and neurotoxicity in
hippocampal neurons following single (Randall and Thayer,
1992) or repeated (Glaum et a1.1990) challenges. This °'Caz+
,., .
~WO 94/08573 . PCT/CA93/00434
- 31 -
deregulation" phenomenon, following its onset could not be
arrested by blockade of Caz+ channels by dihydropyridine
(DHP) nimodipine (1~M), nor by NMDA receptor blockade with
DL-2-amino-5-phosphonovaleric acid (APV; 50~,M). Also, it was
not immediately reversible in many neurons by switching to
a zero-Ca2+ buffer, indicating that this second rise in [ Ca2+ ]
did not result from non-specific plasma membrane leakiness,
but more likely from a decompensation of cellular Ca2+
homeostatic mechanisms. The process of Ca2+ deregulation
usually preceded positive staining with trypan blue or with
ethidium homodimer, and lasted for up to 30-40 minutes before
membrane lysis as judged by the loss of intracellular fura-2
fluorescence. While not bound by theory, this observation
supports further the notion that secondary Ca2+ overload
precedes severe damage to the neuronal membrane.
a b a e- a Z+ s ev t Ca2* a a u1 t' on a d
neuronal death in vitro.
We have found that the degree of toxicity triggered by
Ca2+ influx into neurons depends not only on a rise in [ Ca2+ ] ~,
but also on the type of Ca2+ influx pathway. In spinal
neurons, Ca2+ influx through NMDA receptor operated channels
was considerably more damaging than the same degree of caz+
rise triggered through other pathways (Tymianski et al.
1992). This is indicative that neurotoxicity is more
pronounced when Caz+ enters neurons through NMDA receptor
channels because they are preferentially co-localized with
those processes which, when activated in an uncontrolled or
excessive manner, lead to the expression of neurotoxicity.
This was confirmed using a method for modulating glutamate-
induced transmembrane Ca2* gradients independently of NMDA
channels. This was achieved by loading neurons with
membrane-permeant forms of various calcium buffers. These
agents chelate Ca2+ once it enters the neuron, but have no
reported effects on NMDA channels. If initiation sites for
neurotoxic cascades are truly localised in close physical
WO 94/08573 PCT/CA93/0043~
- 32 -
proximity to NMDA channels, then fast Caz+-buffers with high
cytomplasmic mobility (eg.~~,~APTA, Kd Ca. l6onM, D~p.L~ approx.
2xlo'~ cmz/sec) should prove neuroprotective by capturing Ca2+
ions as they permeate through NMDA channels before they
diffuse to their neurotoxicity outrigger sites~~ (DC, approx.
0.2x10'9 cm2/sec). By the same token, a calcium buffer with
similar Ca2+ affinity but slower buffering kinetics (eg:
EGTA, Kd also ~. 100nM at pH 7.2) might be less
neuroprotective if it captured Caz+ too slowly, allowing it
sufficient time to reach its neurotoxic site of action.
Spinal neurons in dissociated cultures were
simultaneously loaded with fura 2-AM and with a Ca2+ chelator
(Table 1). They were then exposed to 50 min challenges with
250~M glutamate as described previously. To ensure that
loading with BAPTA-AM and EGTA-AM produced equivalent
concentrations of the two Ca2+ buffers in neurons, the
buffers were present at 100~M concentrations in the loading
medium (approaching saturating concentrations for BAPTA-AM).
The assumption was made that in the presence of excess
membrane-permeant Ca2+ buffer, the limiting factor in buffer
loading would become the intracellular esterase activity,
which presumably, would be equal in neurons from different
experiments.
Figure 2 illustrates representative experiments, showing
that when neurons were pre-treated with 10~M BAPTA-AM (Fig.
2C), the [Ca2+]; transient amplitude was not attenuated as
compared with controls (see Fig. 2B). However, the frequency
of Ca2+ deregulation (asterisks) was markedly decreased.
Pretreatment of neurons with 100~M BAPTA-AM (Fig. 2D), and
100~CM EGTA-AM (Fig. 2E) caused the glutamate-evoked [Ca2+],
transient to be significantly attenuated. This effect was
also accompanied by a decreased proportion of Ca2+
deregulations as compared with controls. By contrast,
neurons which were pretreated with 30~,M of 4,4'-FZBAPTA, a
buffer with a low Caz+ affinity (Kd approx. 460onM), all
succumbed to the 50 min glutamate challenge (Fig. 2F).
Figure 2A shows stability of the recordings throughout the
~.14'~1~~ : . ~:
~WO 94/08573 PCT/CA93/00434
- 33 -
time-period of the experiment.
Figure 3D shows the survival outcomes for all spinal
neurons challenged with 250~M glutamate for 50 min. This
challenge caused Caz+ deregulation and cell death in about
80% of neurons under control conditions (Fig. 3D, CTRL). The
data show that all Ca2+ buffers used in this study with the
exception of 4,4~-FZBAPTA-AM (Rd = 4600nM) were effective in
reducing cell death. Particularly, when loaded into neurons
at equivalent concentrations (100~CM), BAPTA the fast Ca2+
buffer was considerably more neuroprotective than EGTA, the
slower Ca2+ buffer which has similar Caz+ affinity to BAPTA.
This result supports our original hypothesis that Ca2+ must
diffuse relatively short distances within the cytoplasm to
reach its neurotoxic site of action. The results also
demonstrate that [Ca2+]; must rise to micromolar
concentrations in order to trigger neurotoxicity, because
buffers with Kd~s of up to 3600nM (BrZBAPTA) were highly
neuroprotective. The data indicate that Caz+ becomes
neurotoxic when its concentration rises to levels
approximating the Caz+ affinity of 4,4~-FZBAPTA.
Among neurons loaded with Ca2+ buffers, there was a
linear relationship between the fraction of dead neurons in
each experiment and the value of the [Ca2+]; plateau reached
when the initial [Ca2+]; transient decayed to a steady-state
level (Fig. 3C, R = 0.986, p=0.0003). Plateau [Ca2+]; values
in control neurons (not loaded with Ca2+ buffer) did not fall
on the best-fit streight line in this relationship (solid
square, Fig. 3C). This result in control neurons is
consistent with data we have reported previously (Tymianski
et al. 1992), which showed that cytoplasmic Caa+ indices
peak [ Ca2+ ] ;, average [ Ca2+ ] ;, and the area under the [ Caz+ ]
time-course curve) did not correlate with neuronal mortality.
The fact that plateau [Cap+]; correlated highly with cell
death in buffer-loaded neurons in this study shows that the
exogenously administered Ca2+ buffers dominated over other
cellular Ca2+ homeostatic processes. Thus, the probability
of cell death becomes a function of [Ca2*];, rather than that
~ ~. 4'~ ~ ~v ; ~ ~ ..
WO 94/08573 PCT/CA93/0043
v3 4 -
of other cellular homeostatic processes.
Figure 3A shows that plateau [Ca2+J; in neurons loaded
with BAPTA and~its derivatives was clamped at a level
logarithmically proportional to the buffer's Ca2+ affinity.
There was a similar relationship between the fraction of dead
neurons in each experiment, and the buffer's Ca2+ affinity
(Fig. 3B). These relationships did not hold in the case of
EGTA. A possible explanation for this is the latter buffer's
slow buffering speed as compared with that of the BAPTA
derivatives. Another possibility is that as intracellular pH
decreases during cell death, the affinity of EGTA for Ca2+
decreases, as this buffer is highly pH sensitive.
PART 2: Brain Slice Experiments.
The above experiments show that exogenously applied Caa+
buffers are neuroprotective against glutamate-induced
neuronal death. The following experiments were performed to
show that these agents are successfully delivered into
neurons 'fir vivo (see above for methods).
Photographic evidence was obtained showing that
fluorescent BAPTA derivatives reach and permeate into target
CNS neurons when applied intravenously in the whole animal.
Adult Fischer 344 rats were anaesthetized with 1.5% halothane
and 70%/30% Nitrous/CO2. Calcium crimson-AM,a BAPTA
derivative with an excitation maximum at 590nm, was dissolved
in DMSO and injected intravenously by infusion pump. Control
animals received DMSO alone. Following this, the rats were
decapitated, and transverse brain slices (400 um) were
obtained and viewed with a laser-scanning confocal microscope
(Bio-Rad MRC 600). Control and loaded slices were viewed
with the same confocal settings.
The confocal microscopy images taken from rat brain
slices show that Calcium Crimson-AM, a fluorescent derivative
of BAPTA, could be delivered via intravenous infusion (see
Fig. 2A) into neurons in the hippocampal CA1 region and into
cortical neurons. To ensure its solubility in rat blood and
in extracellular fluid, Calcium Crimson-AM was dissolved in
DM80 (400~cg in 0.5m1). It was clearly demonstrated that in
WO 94/08573
PCT/CA93/00434
- 35 -
control brain slices with DMSO alone, there was little or no
visible fluorescence. By contrast, the fluorescence of
Calcium Crimson was clearly visible in individual cortical
and hippocampal CA1 neurons in slices taken from rats loaded
with this Ca2+ buffer. This showed the loading of membrane-
permeant Caa+ buffers into individual CNS neurons via
intravenous infusion.
PART 3' Experiments IN VIVO.
The above results show that membrane-permeant Ca2+
buffers were neuroprotective in spinal neurons,~nn v'tro, and
that they could be successfully delivered into the mammalian
CNS. We have further shown that intracellular Ca2+ chelation
using exogenously-administered Ca2+ buffers is as a useful
neuroprotective strategy ~~ vivo. Figure 4 shows
representative results from experiments in a first study, in
which the neuroprotective effects of BAPTA-AM (l8mg/kg
delivered in 0.5m1 DMSO) were evaluated in a rat cortical
stroke model. Figure 4 shows that cortical stroke volumes
were markedly attenuated in rats treated with BAPTA-AM
(shaded areas in Figure 4 left panel) as compared with
controls (Figure 4 right panel) . Cortical infarction volumes
were evaluated using two independent techniques: TTC and
histology (see methods section above). Figure 5B shows that
both. methods were reliable for assessing cortical infarction
volume. The outcome of the first in vivo study is shown in
figure 5A: There was a marked reduction in cortical stroke
volume in rats treated with BAPTA-AM, as compared with
controls. Control rats sustained stroke volumes of 38.32%
~ 10.95% and 46.14% ~ 9.52% (mean ~ standard deviation) using
the TTC and histological assessments respectively. By
contrast, rats pre-treated with BAPTA-AM sustained stroke
volumes of 19.58% ~ 5.41% and 20.62% ~ 7.42% using the TTC
and histology assessments respectively. Thus, the
pretreatment of animals with BAPTA-AM accomplished a 50%
reduction in cortical stroke volume (p=0.008 and 0.001 for
TTC and histology, respectively).
WO 94/08573 PGT/CA93/0043~
- 36 -
The second study in the same rat stroke model (see
methods section), using BAPTA-AM, as well as 5,5'-FZBAPTA-AM
and 4,4'-FZBAPTA-AM encompassed a total of 38 rats and 5
groups (7-8 rats per group). BAPTA and its derivatives 4,4'
and 5,5' difluoro BAPTA were infused over fifty minutes into
rats at a dosage of 18 mg per kg and 0.5 cc's of DMSO. To
test whether infarctions produced in rats receiving DMSO
alone were larger than usual, we added a group which received
0.5 ccs of saline, as a second control. Figure 6 shows that
rats treated with BAPTA-AM or its two derivatives had
sustained substantially lower infarction volumes than either
the DMSO or saline controls. The reduction in volume of
infarction stand from 50 percent with 4, 4' and 5, 5' difluoro
BAPTA to 55 percent with BAPTA-AM alone, as compared with the
DMSO alone groups. The results were statistically
significant at p50.05 for 4,4'F2 BAPTA-AM and p<_0.005 for
BAPTA-AM and 5,5'F2 BAPTA-AM.
' We have further confirmed that the relationships
observed between Ca2* buffering capacity and neuronal
survival observed in the above tissue culture experiments
(Figure 3B) are reproduced ~ vivo The importance of this
lies in ,the fact that since equivalent neuroprotection is
achieved with Ca2* buffers with low Ca2* affinity (high Kd) ,
these agents are less likely to interfere with the normal
functioning of neurons.
~xamnle of a Pharmaceutical Composition
~cordina to the Invention
A solution of dimethylsulphoxide containing 1% w/v of
BAPTA-AM was prepared by the dissolution of BAPTA-AM in
dimethylsulphoxide solvent a pharmaceutically acceptable
carrier therefor.
While the invention has been described in detail and
with reference to specific embodiments thereof, it will be
apparent to one skilled in the art that various changes and
modifications can be made therein without departing from the
~14'?~2~
WO 94/08573 PCT/CA93/00434
- 37 -
spirit and scope of the invention as described and claimed.
